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Abstract
Background: Herein is hypothesised that a comprehensive optical coherence tomography (OCT)-
-guided implantation protocol for bioresorbable scaffolds (BRS) can improve expansion and apposition, 
thus resulting in better clinical outcomes, particularly in reducing thrombotic events.
Methods: Patients considered suitable for BRS therapy in de novo coronary lesions underwent OCT. 
The predominant type of plaque was classified as lipidic, fibrous or calcific. Accordingly they under-
went tailored plaque preparation. After proper sizing, BRS was deployed and final OCT was acquired. 
Post-dilation was performed only in cases of suboptimal deployment. Procedural and 12 month clinical 
follow-up is reported.
Results: Twenty nine patients (41 lesions) who were considered clinically and angiographically 
suitable for BRS were enrolled, including challenging clinical scenarios such as ST-segment eleva-
tion myocardial infarction or CTOs. The OCT-guided protocol was feasible in 90.2% of the lesions:  
14 (37.8%) lipidic, 11 (29.7%) fibrous, and 12 (32.4%) calcific. Three (8%) lesions classified as cal-
cific were changed to treatment with metallic stent. BRS were implanted in 34 (91.9%) lesions, thereof  
30 (88.2%) with optimal deployment in OCT. One (3.6%) periprocedural MI occurred, resulting in 
3.6% target vessel failure and 0% scaffold thrombosis of any kind after a 12 month follow-up.
Conclusions: OCT-guided BRS implantation is feasible in 90.2% of de novo lesions and results in 
optimal expansion and apposition, correlating with 3.6% incidence of target vessel failure and 0% scaf-
fold thrombosis at 12 m follow-up, probably due to better selection of lesions amenable for BRS treatment 
and to a possibility of tailoring intervention to the type of plaque. These encouraging pilot results require 
confirmation in larger clinical studies. (Cardiol J 2018; 25, 4: 443–458)
Key words: tomography, optical coherence, bioresorbable scaffold, percutaneous  
coronary intervention
Introduction
The advent of bioresorbable scaffolds (BRS) 
has been heralded as the fourth revolution in in-
terventional cardiology, culminating three preced-
ing cornerstones: balloon percutaneous coronary 
intervention (PCI), bare-metal coronary stents 
(BMS) and drug-eluting stents (DES) [1]. The 
concept of transiently scaffolding the coronary 
artery during the minimal period after PCI, which 
444 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 4
is required to avoid acute closure, recoil and 
negative remodeling was of the utmost appeal [2]. 
The bioresorption ultimately results in the com-
plete removal of all foreign material from the 
vessel wall, thus restoring vasomotion and normal 
physiology, avoiding the jailing of side branches, 
as well as reducing chronic inflammatory stimulus 
and mechanical stress on the vessel. This was 
theoretically expected to translate into eradication 
of very-late device thrombosis, and a substantial 
reduction of restenosis, neoatherosclerosis and 
late catch-up. 
Nonetheless, all these foreseen theoretical 
advantages are failing to be empirically demon-
strated in a clinical scenario hitherto. After initially 
encouraging results [3–9], BRS resulted in much 
higher device thrombosis rates than DES [10–13], 
most of them occurring acute or subacutely [10], 
but remained high in late and very late phases 
[11–14]. Furthermore, the incidence of periproce-
dural myocardial infarction (MI) and occlusion of 
small side branches were both higher in BRS than 
DES, due to the larger size of their struts [15], 
and cases of neoatherosclerosis have also been 
reported [16, 17]. The reasons for this mismatch 
between obvious theoretical advantages of BRS 
and their poorer-than-expected clinical perfor-
mance remains unclear. The role of incomplete 
scaffold apposition (ISA) has been perhaps over-
emphasised, even though evidence linking acute 
ISA with device thrombosis is indirect and weak 
[18–20]. Rupture of the scaffold structure [21, 22] 
or underexpansion of the device [11, 23–25] might 
likely explain cases of device failure. Indeed in 
most cases of scaffold thrombosis a mechanical 
cause can be identified in optical coherence to-
mography (OCT) [26].
Bare-metal coronary stents have very distinct 
physical properties from metallic DES: they are 
more fragile and prone to rupture, so deployment 
must be performed carefully, paying special atten-
tion to calcium [21, 27, 28]. In addition, they have 
limited overexpansion capacity [27–29], so an ac-
curate sizing is crucial. Therefore BRS cannot be 
implanted as a conventional metallic stent: they 
require a BRS-dedicated implantation protocol, 
which takes into account their specific physical 
properties and peculiarities. The clinical outcome 
after BRS implantation improves sensibly with sys-
tematic use of quantitative coronary arteriography 
for accurate sizing [30] or after implementation of 
BRS-dedicated implantation protocols [11]. When 
the first approved BRS obtained the CE-mark in 
2011, the manufacturer and experts recommended 
an angiography-guided implantation protocol [30], 
notwithstanding the limitations of angiography to 
assess critical features for accurate deployment, 
such as plaque composition, expansion, scaffold 
rupture or even for precise sizing if confounding 
elements (like calcium, foreshortening or vessel 
overlap) are present. At that time OCT was not as 
widespread as it is nowadays and it was considered 
rather a research tool without clear clinical applica-
tions. Nonetheless OCT is progressively generat-
ing an interesting corpus of evidence and already 
has clinical indications endorsed by the guidelines 
[31]. As a consequence, OCT is amply available 
in academic and non-academic centres now, so an 
OCT-guided implantation protocol for BRS would 
be currently feasible and could be adopted by 
a majority of implanting centres. 
It is hypothesised herein that OCT-guided 
implantation protocol for BRS can accurately as-
sess all anatomical variables that can interfere 
with optimal deployment, thus enabling a finely 
tailored BRS implantation that may translate into 
improved clinical outcomes. The goal of the cur-
rent pilot study is to test the feasibility and safety 
of a protocol proposal to be used in larger, future 
studies to test this hypothesis.
Methods
This is a descriptive single-center pilot study 
to test the feasibility and safety of an OCT-guided 
implantation protocol for BRS, taking into account 
the physical properties of the device, the current 
evidence as well as the experience of the inves-
tigators. 
Study population
Consecutive patients with an indication for 
PCI in the Hospital of Frankfurt Oder (Germany) 
and with coronary lesions considered angiographi-
cally suitable for BRS implantation were included 
in this study. Exclusion criteria were: 1) age > 80 
years old; 2) creatine clearance < 30 mL/min; 3) 
hemodynamic instability; 4) active bleeding; 5) any 
condition conferring a life expectancy < 10 years; 
6) excessive tortuosity; 7) severe calcification in 
the angiography; 8) target lesion involving the 
left main; 9) in-stent restenosis; 10) ostial lesion; 
11) target lesion in a by-pass graft; 12) reference 
vessel diameter < 2.25 mm or > 4 mm; 13) opera-
tor not certified for BRS implantation; 14) opera-
tor unable to acquire quality OCT or to properly 
interpret it; 15) mismatch between the lesion size 
and the size of the available BRS devices.
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The study was conducted according to the 
Declaration of Helsinki. Since all the steps in the 
hereby described intervention conform to cur-
rently approved standards of good clinical practice 
and only data stemming from a single centre were 
analyzed, the approval of the Ethics Committee 
could be waived and no specific informed consent 
was provided to the patients, other than the ones 
conventionally used for PCI with BRS and for the 
use of invasive imaging. 
Study devices
The protocol applies the three BRS currently 
available in Europe: two polylactide-based BRS 
(ABSORB, Abbott Vascular, Santa Clara, CA, USA; 
DESOLVE, Elixir Medical Corp., Sunnyvale, CA, 
USA) and one magnesium BRS (MAGMARIS, 
Biotronik AG, Bülach, CH).
The ABSORB (Abbott Vascular, Santa Clara, 
CA, USA) consists of a semi-crystalline poly(L-lac-
tide) backbone and conformal coating of amorphous 
poly (D,L-lactide) that carries the antiproliferative 
drug everolimus. The scaffold is designed as in-
phase sinusoidal hoops, with 6 peaks and valleys 
per hoop and 3 straight longitudinal connectors 
linking peak-to-peak of adjacent hoops [32]. The 
strut thickness in radial direction is 158 µm [33], 
while the width in the circumferential direction is 
191 µm for the hoop and 140 µm for the connector 
(Fig. 1) [27]. The molecular weight of polymers is 
degraded primarily through hydrolysis of the ester 
bonds present in each monomer subunit. Crystalline 
residues > 2 µm are phagocytosed by macrophages. 
Ultimately, the poly-lactide polymers degrade to lac-
tate, which is metabolised via Krebs’ cycle and other 
metabolic pathways, resulting in CO2 and H2O [34].
The DESOLVE (Elixir Medical Corp., Sun-
nyvale, CA, USA) is a poly-lactide-based BRS, 
eluting the antiproliferative drug novolimus. The 
scaffold is also designed as in-phase sinusoidal 
hoops, with a variable number of peaks and valleys 
per hoop, depending on the calibre of the device 
(9 peaks and valleys in the 3 mm DESOLVE) and 
also 3 straight longitudinal connectors linking 
peak-to-peak of adjacent hoops. The most proximal 
and most distal hoops are however out-of-phase, 
so peaks and valleys connect directly. The strut 
thickness in radial direction is 150 µm, while the 
width in circumferential direction is 165 µm for the 
hoops and 100 µm for the connector (Fig. 1) [28].
Figure 1. Composition, design and technical specification of bioresorbable scaffolds included in the study; 
OCT — optical coherence tomography; PLLA — poly-L-lactic acid.
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The MAGMARIS (Biotronik AG, Bülach, CH) 
consists of a proprietary magnesium alloy and con-
formal coating of amorphous poly(L-lactide) that 
carries the antiproliferative drug sirolimus. The 
scaffold is designed as in-phase sinusoidal hoops, 
with 6 peaks and valleys per hoop and 2 sinusoidal 
longitudinal connectors linking the slopes between 
peaks and valleys of adjacent hoops [35]. The strut 
thickness in radial direction is 150 µm, while the 
width in circumferential direction is 140 µm for the 
hoops and 80–100 µm for the connector (Fig. 1). 
The magnesium (Mg) resorption takes place in 
two steps: firstly, the Mg alloy reacts with water to 
create Mg-hydroxide; secondly, the Mg-hydroxide 
is slowly converted to amorphous calcium phos-
phate with high water content [36]. There is scarce 
bench-testing data from magnesium BRS (MgBRS) 
as from polylactide-based BRS [35]. Until more 
detailed information is available, it is reasonable 
to assimilate the MgBRS to polylactide BRS and 
hence following a cautionary imaging-guided im-
plantation protocol.
OCT-guided BRS implantation protocol
PCI preparation and OCT acquisition. The 
PCI was performed via radial or femoral access with 
a ≥ 6 F guiding catheter. A conventional 0.014” PCI 
wire as per operator choice was advanced distally 
to the target lesion. In case of ST-elevation MI with 
thrombolysis in myocardial infarction (TIMI) 0 flow 
or angiographic image of thrombus [37], aspiration 
thrombectomy was encouraged before OCT acqui-
sition. OCT pre-intervention was acquired with 
a Dragonfly catheter and an Ilumien Optis console 
(St. Jude Medical, St. Paul, MN, USA) at a rotation 
speed of 180 Hz and a pullback speed of 18 mm/s, 
according to a non-occlusive technique [38]. Other 
pullback speeds were allowed if the operator justi-
fied the decision due to need of sparing contrast 
in patients with advanced renal insufficiency, long 
lesions or requiring multiple pullbacks.
OCT pre-intervention: the critical step. 
The OCT-pre was analyzed by an operator online 
with two specific aims: to select an accurate sizing 
and to evaluate histological type of plaque (Fig. 2). 
Proximal and distal landing zones were se-
lected, as defined by the closest plaque-free cross-
sections to the point of minimal lumen area (MLA) 
in the proximal and distal reference segments, 
respectively. If these definitions could not be met, 
the operator could select the landing zones by 
approximation (least diseased cross-section with 
functionally non-obstructive lumen area) or based 
in other interventional criteria, like preservation 
of side-branches. The length of the scaffolding-
requiring segment (SRS) was measured between 
the cross-sections of the proximal and distal landing 
zones. The proper size of the BRS was then se-
lected, so the diameter did not differ by more than 
0.5 mm with any of the maximal lumen diameters 
in the landing zones and length exceeded was at 
least 2 mm proximally and distally to length of the 
Figure 2. Optical coherence tomography (OCT)-guided bioresorbable scaffold implantation protocol; DES — drug-
-eluting stent; NC — non-compliant balloon.
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SRS. In cases where the difference in diameter 
were > 0.5 mm in any of the landing zones, then 
an overlapping-BRS strategy should be consid-
ered, or the DESOLVE device (with accredited 
larger post dilation capabilities) was favoured. The 
length of BRS could be also adjusted according 
to interventional criteria, such as a wish to avoid 
BRS edge overhanging or jailing the take-off of 
side branches [39].
The type of plaque was assessed in the cross-
section of MLA, which is automatically detected 
by current OCT software, and classified as lipidic, 
fibrous or calcific (Fig. 3). A lipidic plaque was 
defined as a low backscattering (hypointense) area 
very close to the lumen contour (< 300 µm) with 
very high attenuation (casting a shadow behind). 
A fibrous plaque was defined as tissue with high 
backscattering (hyperintense) throughout the 
plaque or at least in the most adluminal 300 µm, 
extending to a sector ≥ 135°. Finally, a calcific 
plaque was defined as a low backscattering (hy-
pointense) area, at any depth between lumen and 
adventitia, but with low attenuation (no shadow 
behind), extending to a sector ≥ 135°. In cases of 
mixed patterns of plaque, or cross-sections meet-
ing two or more definitions, the adjudication of type 
of plaque was done in a hierarchical manner, having 
priority given to calcific type, followed by fibrous 
and finally lipidic type. After having classified the 
type of plaque in MLA cross-section, the operator 
swept the proximal and distal segments of SRS. In 
cases where a different and higher hierarchy type 
of plaque were present in > 50% of any proximal 
or distal segments to MLA, then the plaque was 
hierarchically reclassified.
Plaque preparation and scaffold deploy-
ment. If the plaque was lipidic, then a 1:1 pre-
dilation with a non-compliant (NC) balloon was 
performed. If adequate expansion of the balloon 
was observed in the angiography, then the scaf-
fold was deployed as previously described [11]. 
Fibrous plaques cannot be detected in angiogra-
phy, but can prevent adequate expansion of BRS, 
even though sometimes the predilation balloon 
expands correctly in the angiography. Based on 
this observation, fibrous plaques ought to un-
dergo plaque modification with scoring or cutting-
balloons. If the plaque was calcific, the operator 
had to reconsider the suitability of the lesion for 
BRS and eventually be convinced to switch to a 
metallic DES. If the operator still preferred BRS, 
then aggressive plaque modification with scoring- 
or cutting-balloons was mandatory. The plaque 
modification could be substituted by debulking 
with rotablation, if chosen by  the operator in 
cases of calcific plaques (Fig. 2).
After plaque modification or debulking, the 
acquisition of another OCT pullback before scaf-
fold deployment was compulsory in order to assess 
whether the modification had efficiently disrupted 
stricture areas and to check that no structural bar-
rier remained in the artery that could prevent an 
adequate expansion. If these points could not be 
verified, the operator had to decide between per-
forming further modification plus subsequent OCT 
iterations or switching to a metallic DES (Fig. 2). 
Figure 3. Type of plaque in optical coherence tomography. A. Lipidic plaque: low backscattering (hypointense) area 
very close to the lumen contour (< 300 µm) with very high attenuation (casting a shadow behind); B. Fibrotic plaque: 
high backscattering (hyperintense) throughout the plaque or at least in the most adluminal 300 µm, extending to 
a sector ≥ 135°; C. Calcific plaque: low backscattering (hypointense) area, at any depth between lumen and adventitia, 
but with low attenuation (no shadow behind), extending to a sector ≥ 135°.
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The sizing of the scaffold could be readjusted after 
this intermediate OCT pullback.
The scaffold was deployed following manufac-
turer recommendations: slow inflation (2 atmos-
pheres every 2 s) and keeping maximal pressure 
for > 30 s in polylactide BRS; whilst in MgBRS 
inflation could be performed at ordinary speed 
and keeping the maximal pressure for a prolonged 
interval was just optional.
OCT post-intervention. A repeat OCT pull-
back was acquired after scaffold deployment, fol-
lowing the same procedure as previously described, 
aiming at three specific parameters: expansion, 
apposition and rupture.
Expansion was quickly assessed online with 
the tool “lumen profile” of the Ilumen Optis soft-
ware. The region of interest (ROI) was delimited 
by the scaffolded segment (most distal and most 
proximal cross-section in which struts were vis-
ible in all sectors of the circumference) and then 
MLA was automatically detected. If MLA was 
< 80% than both any proximal or any distal refer-
ence cross-sections within the ROI, the scaffold 
was considered underexpanded. Likewise, if severe 
ellipticity was found in any frame (ellipticity index 
> 1.6), the scaffold was considered underexpanded 
as well, irrespective of its area. Ellipticity index 
was calculated by dividing the major diameter 
between the minor diameter of a cross section. In 
case of underexpansion, postdilation with an NC-
-balloon of the same size as the scaffold or 0.5 mm 
greater in calibre was mandatory.
Due to translucency of the polylactide poly-
mers, ISA can be assessed directly in polylactide 
BRS [40]. Nonetheless Mg alloy is not translucent, 
so apposition in the MgBRS must be assessed 
as with metallic stents [40]. In order to propose 
a homogeneous criterion, valid for all BRS enrolled 
in this study, an ISA distance was chosen to be the 
distance between the adluminal edge of struts and 
lumen contour, in a line connecting the center of 
the adluminal strut edge with the center of gravity 
of the vessel, > 400 µm was recommended thresh-
old for optimization, since smaller ISA distances 
have proven to heal spontaneously in metallic 
DES [19]. In cases of an ISA distance > 400 µm, 
postdilation with a NC-balloon 0.5 mm larger than 
the nominal BRS calibre was recommended. Only if 
a DESOLVE BRS was implanted, in cases of severe 
ISA or postdilation with a NC-balloon 1.0 mm larger 
than the nominal BRS calibre was allowed.
Scaffold rupture was defined as the presence 
of stacked or overhanging struts in any cross-
section [22]. Two-dimensional-cross-sectional im-
ages were preferred for the assessment, because 
current OCT image-fusion (commonly dubbed 
3D-OCT) is neither accurate nor reliable enough 
for this aim, particularly in BRS. Since scaffold 
rupture, even at subtle degrees, can be unstable 
and result in chronic repeat mechanical stress and 
incomplete vessel healing, cases of BRS rupture 
ought to be fixed and stabilised by implantation of 
a metallic DES.
Objectives and clinical follow-up
The main objectives of the study were the 
feasibility and safety of the OCT-guided BRS im-
plantation protocol. Feasibility was defined as the 
proportion of interventions in which the protocol 
could be completed without violation in all inter-
ventions in which the protocol was planned. Safety 
was assessed as periprocedural complications 
and cumulated incidence of target vessel failure 
(cardiac death, vessel-related MI and target vessel 
revascularization) during the in-hospital period or 
at the 30th day follow-up, whichever was longer. 
Secondary objectives were patient-oriented com-
posite of all-cause death, MI or revascularization, 
together with individual components of composites, 
stent thrombosis, stroke, vascular complications, 
angiographic success (defined as < 20% diameter 
stenosis by visual estimation and TIMI 3 flow in the 
target vessel at the end of intervention) and pro-
cedural success (defined as angiographic success, 
plus absence of patient-oriented endpoint in the 
hospital phase or up to 30 day follow-up, whichever 
was longer), which conforms to Academic Research 
Consortium recommendations and definitions [41].
Telephone or visit follow-up were scheduled at 
30 days, 6 months, 12 months and yearly for up to 
5 years after the intervention. Due to the recent 
publication of discouraging clinical outcomes in BRS 
[12, 13] it was decided by the study investigators 
to communicate hereby at the interim 12-month 
follow-up results to date, without waiting for the 
completion of the inclusion and follow-up, to meet 
the need of suggesting a possible future direction, 
potentially enabling improved clinical outcomes.
Statistical analysis
Continuous variables following Gaussian dis-
tribution were reported as mean ± standard devia-
tion, whilst they were reported as median (Q1–Q3) 
whenever a normal distribution could not be as-
sumed. Nominal variables were reported as count 
(percent). Cumulated incidences are presented as 
proportions, calculated with respect to the total 
number of patients in whom OCT-guidance was 
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feasible. All statistical analysis were performed 
using the IBM SPSS 20.0 (IBM Corp, Armonk, NY, 
USA) software package.
Results
Between January and July 2016, 29 patients 
(41 lesions) undergoing PCI in Hospital Frankfurt 
(Oder) in Germany were considered clinically and 
angiographically suitable for BRS implantation 
were included in the study. Tables 1 and 2 present 
clinical and angiographic characteristics of patients 
and lesions included, respectively. 
In 1 patient (4 lesions) the OCT-pre could not 
be obtained due to excessive tortuosity of vessels. 
After analysis of OCT-pre, 14 (37.8%) lesions were 
classified as lipidic, 11 (29.7%) lesions as fibrous 
and 12 (32.4%) lesions as calcific (Table 3, Fig. 4). 
All lesions with lipidic plaque underwent un-
problematic NC-balloon predilation and scaffold 
deployment. The OCT-post did not detect any 
cases of underexpansion, or BRS-rupture. Only 
1 (7.1%) case presented ISA > 400 µm that could 
be corrected after targeted optimisation, so that all 
scaffolds (100) could be optimally deployed.
Eight (72.7%) fibrotic lesions underwent 
plaque modification with scoring balloon (Angio-
sculpt, Biotronik AG, Bülach, CH) and 3 (27.3%) 
with cutting-balloon (Flextome, Boston Scientific, 
Marlborough, MA). In 2 (18.2%) cases initially 
treated with scoring balloon, the OCT after plaque 
modification showed insufficient plaque disrup-
tion or persistence of structures jeopardising an 
optimal scaffold expansion, so a second dilation 
with scoring-balloon was required. In both cases, 
the second intermediate OCT showed sufficient 
plaque preparation and scaffolds could be deployed 
achieving optimal expansion, with no case of ISA 
requiring further optimization and no BRS rup-
ture. Nonetheless, in the case requiring a second 
plaque modification with cutting-balloon, coronary 
rupture with pericardial tamponade occurred. The 
rupture was successfully handled with gentle 
compliant balloon inflation at the leak site (three 
consecutive inflations of 60 s, with deflation 
pauses of 10 s in between) and pericardiocentesis. 
After restabilising the patient hemodynamically, 
the final OCT pullback showed optimal deploy-
ment of the scaffold and a completely sealed 
coronary artery. Cardiac markers raised over 
3 × ULN, but the patient had neither chest pain 
nor repolarisation changes in electrocardiogram. 
The patient could be uneventfully discharged 
7 days after intervention (Fig. 5).
In 3 out of 12 (25.0%) lesions with calcific 
plaque, the operator decided to switch to a metal-
lic DES, due to massive calcification observed in 
OCT-pre, jeopardising an optimal scaffold deploy-
ment notwithstanding an aggressive and complex 
plaque preparation. Three (25.0%) calcific lesions 
underwent plaque modification with scoring balloon 
and 5 (41.7%) with cutting-balloon. Two of them 
required one further iteration, but both scaffolds 
were optimally deployed. In 2 cases the OCT in-
between was obviated due to the complexity of the 
procedure (CTO) and in both cases the final de-
ployment was suboptimal due to underexpansion. 
One case met the definition of underexpansion due 
to ellipticity index > 1.7, even though measured 
scaffold areas were quite uniform along the scaf-
folded segment. It corresponded to a chronic total 
occlusion in which proximal and distal true lumina 
had been connected through subintimal tracking. In 
the segment of subintimal scaffolding, the collapsed 
true lumen abutted into the neolumen created in 
the subintimal space, thus deforming the scaffold 
which was responsible for the high ellipticity index 
[42]. In this case, two NC-balloon inflations (with 
the same size of the scaffold and 0.5 mm bigger 
in diameter, respectively) left the ellipticity index 
exactly as it was at the beginning (Fig. 6). Finally, 
1 (8.3%) calcific plaque underwent rotablation 
with 1.5 mm burr, followed by successive plaque 
modification with a scoring balloon. After these 
manoeuvres scaffolds could be deployed success-
fully. ISA > 400 µm was detected at the OCT post, 
but it could be corrected with post-dilation, thus 
achieving an optimal result.
According to the above reported data, the 
feasibility of OCT-guided protocol was 90.2% of 
initially enrolled lesions. BRS could finally be 
implanted in 34 (91.9%) of the lesions undergoing 
OCT-guided protocol. 1 patient formally suffered 
periprocedural MI after prolonged intervention 
of a complex CTO (Table 4), asymptomatic and 
with normal systolic function in echocardiogram. 
At 12-month follow-up, 1 patient had died due to 
urosepsis and another patient underwent PCI due 
to non-ST-segment elevation MI in a non-target 
vessel (Table 4). These data correspond to an an-
giographic success of 100% and a procedural suc-
cess of 96.4%. There was no incidence of definite, 
probable or possible stent thrombosis.
Discussion
The main findings of this study can be summa-
rised as follows: 1) OCT-guided BRS implantation 
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Table 1. Clinical characteristics of the patients.
Initially enrolled (n = 29) Finally treated with BRS (n = 25)
Male 22 (75.9%) 18 (72.0%)
Age [years] 69.12 (60.09–69.11) 70.18 (62.53–77.85)
Body mass index 28.09 (25.06–31.37) 28.09 (24.50–31.37)
Cardiovascular risk factors:
Hypertension 24 (82.8%) 21 (84.0%)
Hypercholesterolemia 11 (37.9%) 9 (36.0%)
Diabetes mellitus:
Type 2 on OAD 13 (44.8%) 12 (48.0%)
Type 2 insulin-requiring 1 (3.4%) 1 (4.0%)
Smoking:
Non smoker 21 (72.4%) 19 (76.0%)
Previous smoker 2 (6.9%) 1 (4.0%)
Current smoker 6 (20.7%) 5 (20.0%)
Family history of CHD 0 (0.0%) 0 (0.0%)
Previous MI 6 (20.7%) 5 (20.0%)
Previous revascularization:
PCI 12 (41.4%) 11 (44.0%)
CABG 1 (3.4%) 1 (4.0%)
GFR (Cockroft-Gault [mL/min]) 90.44 (56.56–124.36) 80.23 (51.28–124.22)
Serum hemoglobin [g/dL] 13.27 (11.95–14.61) 13.37 (12.08–14.84)
LVEF [%] 65 (45–71) 65 (45–71)
Clinical indication:
Prognostic indication 10 (34.5%) 9 (36.0%)
Stable angina 12 (41.4%) 9 (36.0%)
Unstable angina 2 (6.9%) 2 (8.0%)
NSTEMI 4 (13.8%) 4 (16.0%)
STEMI 1 (3.4%) 1 (4.0%)
Procedural variables:
LM disease 3 (10.3%) 2 (8.0%)
LAD disease 19 (65.5%) 16 (64.0%)
LCx disease 20 (69.0%) 17 (68.0%)
RCA disease 16 (55.2%) 14 (56.0%)
Syntax score 9.00 (5.00–20.75) 9.00 (4.50–24.00)
Contrast volume [mL] 230 (159–300) 238 (170–300)
Dose-area product [Gy × cm2] 152.63 (58.46–180.97) 152.63 (57.46–179.02)
Fluoroscopy time [min] 18.00 (11.48–22.40) 17.07 (11.33–20.48)
Medication at discharge:
ASA 29 (100%) 25 (100%)
Clopidogrel 22 (75.9%) 18 (72.0%)
Prasugrel 4 (13.8%) 4 (16.0%)
Ticagrelor 3 (10.3%) 3 (12.0%)
Warfarin 1 (3.4%) 1 (4.0%)
Rivaroxaban 0 (0.0%) 0 (0.0%)
Dabigatran 1 (3.4%) 1 (4.0%)
Data presented as number (percentage) or as median (Q1–Q3). ASA — acetylsalicylic acide; BRS — bioreorbable scaffolds; CABG — coronary 
artery bypass graft; CHD — coronary heart disease; GFR — glomerular filtration rate; LAD — left anterior descending; LCx — left circumflex; 
LM — left main; LVEF — left ventricular ejection fraction; MI — myocardial infarction; NSTEMI — non-ST-elevation myocardial infarction; 
OAD — oral antidiabetics; PCI — percutaneous coronary intervention; RCA — right coronary artery; SB — side branch; STEMI — ST-segment 
elevation myocardial infarction
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protocol is feasible in 90.2% of de novo lesions, in 
a high complexity setting with minimal exclusion 
criteria; 2) OCT enables identification of three dif-
ferent types of plaque, with differing mechanical 
behaviours during BRS implantation, and to tailor 
intervention accordingly; 3) OCT allows for a most 
refined selection of patients for BRS implantation, 
excluding a subgroup of angiographically suitable 
patients in whom suboptimal deployment might 
be anticipated; 4) OCT-guided BRS implantation is 
safe and effective, resulting in optimal angiographic 
success, a minimal incidence of underexpansion 
or severe malapposition and completely avoiding 
scaffold rupture during the implantation. These 
optimal angiographic and imaging results correlate 
clinically with very low rates of periprocedural, in-
hospital and 12-month adverse events, preventing 
the occurrence of early or late scaffold thrombosis. 
It has been sufficiently demonstrated that 
the high risk of scaffold thrombosis with BRS is 
partly due to an unwary implantation technique. 
Undisputable evidence for this causative associa-
tion was empirically obtained in a Swiss-German 
registry of 1305 patients, in which the incidence of 
scaffold thrombosis was significantly reduced from 
3.3% to 1.0% at 12 months after implementation 
of BRS-dedicated implantation protocol [11]. Still 
the incidence of scaffold thrombosis remained rela-
tively high in subsequent clinical studies which had 
Table 2. Angiographic characteristics of lesions 
and procedural details.
Parameters Lesions  
(n = 41)
Coronary segment (ACC)
Prox RCA 4 (9.8%)
Mid RCA 1 (2.4%)
Distal RCA/PD/PL 3 (7.3%)
Prox LAD 9 (22.0%)
Mid LAD 6 (14.6%)
Dist LAD 2 (4.9%)
Diagonal branches 4 (9.8%)
Prox LCx 4 (9.8%)
Intermediate/OM 6 (14.6%)
Distal LCx 2 (4.9%)
Lesion characteristics
Calcification:
None to little 36 (87.8%)
Moderate to severe 5 (12.2%)
Thrombus:
G0 — No thrombus 39 (95.1%)
G1 — Possible thrombus 1 (2.4%)
G5 — Total vessel occlusion 1 (2.4%)
Bifurcation: 14 (34.1%)
Medina 110 6 (42.9%)
Medina 100 2 (14.3%)
Medina 010 5 (35.7%)
Medina 001 1 (7.1%)
CTO 3 (7.3%)
DS [%] 80.0 (75.0–87.5)
Initial TIMI flow:
TIMI 0 4 (9.8%)
TIMI 3 37 (90.2%)
Procedural variables
Average number of scaffolds/ 
/stents implanted
1.0 (1.0–1.5)
Total number of devices  
implanted:
51
BVS 28 (54.9%)
Desolve 13 (25.5%)
Magmaris 4 (7.8%)
Resolute 6 (11.8%)
Scaffold diameter 3.00 (2.50–3.00)
Scaffold length 23 (18–28)
Overlapping scaffolds 12 (29.3%)
Postdilation 16 (39.0%)
Angiographic result
Final DS [%] 0.0 (0.0–0.0)
Final TIMI flow 3 41 (100%)
Angiographic success 41 (100%)
Table 2 (cont.). Angiographic characteristics of 
lesions and procedural details.
Parameters Lesions  
(n = 41)
Procedural complications (lesion level)
Coronary dissection 5 (12.2%)
Plaque shift 1 (2.4%)
SB occlusion 1 (2.4%)
Coronary rupture: 2 (4.9%)
Balloon occlusion 2 (100%)
Covered stent 0 (0.0%)
Pericardiocentesis 1 (50.0%)
Surgery 0 (0.0%)
Acute thrombosis 1 (2.4%)
Device dislodgement 1 (2.4%) 
Data presented as total number, number (percentage) or as median 
(Q1–Q3). ACC — American College of Cardiology (classification of 
the coronary segments according to ACC); BVS — bioresorbable 
vascular scaffold; CTO — chronic total occlusion; DS — diameter 
stenosis; LAD — left anterior descending; LCx — left circumflex; 
OM — obtuse marginal; PD — posterior descending; PL — postero-
lateral; RCA — right coronary artery; SB — side branch; TIMI — 
thrombolysis in myocardial infarction
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already incorporated strict implantation protocols 
[13]. The causes for this persisting high incidence 
of thrombosis were most likely multifactorial, but 
could partly be explained because of the main 
large-scale BRS studies have followed angiogra-
phy-guided implantation protocols that could not 
adjust to variable mechanical resistance of plaque 
and because of the use of invasive imaging, par-
ticularly OCT, which has been marginal [10–13]. 
The physical properties of BRS materials are very 
different from those of metallic stents: they are 
more fragile, prone to rupture under mechanical 
stress and have sensibly lower Young modulus for 
elastic deformation, so they cannot transmit the 
pressure of the balloon onto the atheroma plaque 
as efficiently as metallic stents. In other words, 
whilst the metal in DES is harder than any plaque 
component, the polymers in BRS are weaker than 
some of the plaque components they are supposed 
to crush and angiography is inherently limited to 
characterise them. The results of the present study 
confirm that current angiography-guided implan-
tation is appropriate for lipidic plaques, in which 
100% of the scaffolds were optimally deployed 
(93% of them without postdilation) following simi-
lar recommendations to the current angiographic 
Table 3. Descriptive summary of the optical coherence tomography (OCT) findings and subsequent  
actions at different steps of the protocol. 
OCT guidance Lesions (n = 37) Reference %
OCT pre 37 (100%) 37 (lesions)
Sizing: 
Proximal RVD [mm] 2.99 (2.57–3.37)
Distal RVD [mm] 2.78 (2.38–3.01)
Lesion length [mm] 18 (13–30)
Type of plaque:
Lipidic 14 (37.8%) 37 (lesions)
Fibrous: 11 (29.7%) 37 (lesions)
Scoring-balloon 8 (72.7%) 11 (fibrous plaques)
Cutting-balloon 3 (27.3%) 11 (fibrous plaques)
Calcific: 12 (32.4%) 37 (lesions)
Scoring-balloon 3 (25.0%) 12 (calcific plaques)
Cutting-balloon 5 (41.7%) 12 (calcific plaques)
Rotablation 1 (8.3%) 12 (calcific plaques)
Switch to DES 3 (25.0%) 12 (calcific plaques)
OCT in-between 18 (90.0%) 20 (fibrous/calcific treated with BRS)
Number of iterations 1.00 (1.00–1.25)
OCT post 34 (100%) 34 (lesions treated with BRS)
Underexpansion (area) 4 (11.8%) 34 (lesions treated with BRS)
Ellipticity index ≥ 1.6 4 (11.8%) 34 (lesions treated with BRS)
Underexpansion (area or ellipticity) 5 (14.7%) 34 (lesions treated with BRS)
ISA > 400 µm 5 (14.7%) 34 (lesions treated with BRS)
Scaffold rupture 0 (0.0%) 34 (lesions treated with BRS)
Optimally implanted scaffold 27 (79.4%) 34 (lesions treated with BRS)
OCT post-optimisation 8 (23.5%) 34 (lesions treated with BRS)
Underexpansion (area) 3 (8.8%) 34 (lesions treated with BRS)
Ellipticity index ≥ 1.6 4 (11.8%) 34 (lesions treated with BRS)
Underexpansion (area or ellipticity) 4 (11.8%) 34 (lesions treated with BRS)
ISA > 400 µm 1 (2.9%) 34 (lesions treated with BRS)
Optimally implanted scaffold 30 (88.2%) 34 (lesions treated with BRS)
Data presented as number (percentage) or as median (Q1–Q3). BRS — bioresorbable scaffold; DES — drug-eluting stent; ISA — incomplete 
scaffold apposition; RVD — reference vessel diameter
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standard [11], but lipidic plaques were only 38% in 
the present series. Conversely, angiography alone 
could be insufficient for fibrous or calcific plaques 
(62% in present series), which involves all of the 
few cases of final suboptimal scaffold deployment. 
Calcium is amply recognised as a foe of BRS and 
can usually be detected in angiography by experi-
enced operators, but angiography might lack the 
sensitivity to detect the level of calcification that 
disqualifies a lesion for BRS therapy as reflected 
by the fact that 8% of the lesions considered an-
giographically suitable for BRS were switched to 
DES after OCT examination. Moreover, neither an-
giography nor gray-scale intravascular ultrasound 
can reliably detect fibrous plaques that have been 
hitherto disregarded. A recent short case series has 
reported BRS underexpansion in fibrous plaques, 
even though the balloon expanded correctly in 
predilation. Considering these data altogether, the 
need for an OCT-guided implantation protocol in 
BRS seems justified until more compelling clinical 
evidence becomes available. 
According to available research, this is the 
first comprehensive OCT-guided decision-tree for 
BRS implantation proposed and clinically tested 
hitherto. It is relevant to highlight that this proto-
col focuses on plaque preparation before scaffold 
deployment, rather than on postdilation. Young’s 
modulus for elastic deformation under compres-
sion in all BRS materials is much lower than in 
metallic DES, therefore once BRS has been de-
ployed and interposed between the balloon and 
vessel wall, it might be too late for an attempt at 
optimization, especially regarding expansion. This 
has been the main reason to emphasise predila-
tion instead of postdilation. The high proportion 
of procedural success and the minimal cumulative 
incidence of clinical events at 12-month follow-up 
might endorse this strategy as feasible and effec-
tive. OCT-guidance enables an accurate selection 
of patients and lesions in real-world conditions, 
as it permits  tailoring intervention for each 
patient, escalating the aggressiveness of plaque 
preparation according to expected mechanical 
resistance of each plaque. Albeit this pilot series 
is modest to infer bold clinical conclusions, the 
results encourage further research in this direc-
tion. An important result worthy of attention is the 
0% incidence of acute, subacute and late scaffold 
thrombosis in this series. In the first real-world 
registries of BRS up to 70% scaffold thrombosis 
was acute or subacute, thus strongly suggesting 
procedural factors as the most likely cause [10]. 
The prevention of thrombotic events by means 
of a strict imaging-guided implantation is in line 
with that interpretation and is reassuring of the 
role played by procedural factors in the risk of 
scaffold thrombosis.
Figure 4. Distribution of types of lesions and different steps of the protocol; BRS — bioresorbable scaffold; 
DES — drug-eluting stent; NC — non-compliant balloon; OCT — optical coherence tomography.
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Figure 5. Case of coronary rupture and cardiac tamponade in patient with fibrotic lesion. A. Lesion in the proximal left 
anterior descending (LAD; red arrows), with plaque extending up to the mid-LAD (yellow arrow); B. Optical coherence 
tomography (OCT) pre was occlusive, but it shows a fibrotic plaque that was treated with cutting-balloon; C. OCT 
after cutting shows how the least diseased sectors of the cross-section (between 2 and 8) are also disrupted by the 
cutting balloon and appear now as a single layer corresponding to the adventitia, whilst the plaque fibrotic plaque 
is displaced into the opposite sector; D. ABSORB deployment after preparation of a fibrotic plaque with cutting-bal-
loon; E. Incomplete plaque coverage distally (red arrows), with plaque extending up to the mid-LAD (yellow arrow); 
F. Predilation with compliant balloon; G. Coronary rupture at the distal edge of the balloon predilation (red arrow), 
with blood extravasation into the pericardium; H. After pericardiocentesis and sealing of the rupture with balloon, 
a second ABSORB could be implanted distally, with good angiographic result; still some intracoronary haematoma 
(yellow arrows) can be distally noticed in the angiography; I. Optimal scaffold deployment in OCT. The patient under-
went uneventful clinical outcome, notwithstanding the severe procedural complication.
The results of this study also highlights the 
limited role of postdilation in BRS, as anticipated. 
Postdilation has been dogmatically adopted as 
an undisputed requirement for optimal BRS im-
plantation, but evidence for this recommendation 
is weak and debatable. In ABSORB Cohort B, 
some adverse events were attributed to aggres-
sive postdilation [7], but posterior studies found 
high-pressure postdilation safe [43]. Nonetheless, 
quantitative analysis of the effect of postdilation in 
BRS suggested a negligible effect on expansion. 
Summarizing, post-dilatation may not be harmful, 
but it seems to be ineffectual. Some evidence about 
the need of postdilation in BRS indeed, stems from 
systematic protocols that included postdilation but 
also aggressive predilation with NC balloons and 
BRS implantation deployed to an adequate balloon 
expansion [11]: systematic protocol improves 
clinical outcomes, but the effect of postdilation 
itself has never been explored. The present study 
reports a limited role for post-dilation: the pro-
portion of optimally deployed scaffolds increased 
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from  79.4% to 88.2% after post-dilating and this 
improvement was mainly due to the correction of 
ISA. The effect of postdilation on BRS underexpan-
sion was marginal: only 1 case could be properly 
expanded. 
Limitations of the study
The current study is a descriptive, single-
center pilot study with a modest sample size. 
Although procedural and clinical results are 
promising, they must be cautiously interpreted 
due to the limited sample size. Furthermore, the 
hereby reported follow-up examines the early and 
late phases only, when scaffold thrombosis could 
be efficiently prevented, but remains uncertain 
whether OCT-guidance would  have had any im-
pact on very late scaffold thrombosis, which may 
to depend on different mechanisms such as me-
chanical instability or repeated stress provoked by 
dismantling [14]. Confirmation of these findings 
in a larger clinical study, making comparisons to 
current angiographic standards is required. Like-
wise, reproducibility of the proposed methodology 
at different centres with different operators needs 
to be evaluated to estimate generalizability of the 
strategy.
Notwithstanding positive clinical outcomes 
of the study, despite one severe procedural com-
plication (coronary rupture), which occurred in 
1 patient. Coronary ruptures of unclear mechanism 
have been reported by other operators after BRS 
implantation [44]. In the present case an undis-
puted cause for the rupture could be elucidated 
after a careful review, although it could be most 
likely attributed to aggressive plaque preparation, 
as suggested by distal coronary haematoma visible 
in angiography and OCT after sealing the perfora-
tion. Nonetheless, the site of rupture was at the 
distal edge of a predilating compliant balloon, hence 
it was far from the point of cutting-balloon inflation. 
Although this complication did not finally result 
in a clinically adverse outcome, it was potentially 
life-threatening and should invite critical appraisals 
of the protocol.
Figure 6. Case of persistent underexpansion due to ellipticity index (EI) > 1.6, notwithstanding repeat postdilation with 
non-compliant-balloons, in a segment of subintimal scaffolding for treatment of a chronic total occlusion; A. Chronic 
total occlusion in the proximal right coronary artery; B. Final angiographic result after implantation of 3 DESOLVE 
scaffolds; C. Proximal reference cross-section (CS); D. Cross-section with minimal scaffold area (mm2, thus not meet-
ing the area criteria for underexpansion, but with EI ≥ 1.6); E. Distal reference CS.
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Conclusions
Optical coherence tomography-guided BRS 
implantation was feasible in 90.2% of de novo le-
sions and resulted in optimal expansion and apposi-
tion of scaffolds, correlating with 3.6% incidence of 
target vessel failure and 0% of early plus late scaf-
fold thrombosis at 12th month of follow-up, probably 
due to a better selection of lesions amenable for 
BRS treatment and to the possibility of tailoring 
intervention to predominant type of plaque. These 
encouraging pilot clinical results need to be con-
firmed in larger clinical studies.
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